Summary & Overview
CPT 1020T: Raman Spectroscopy for Skin Lesion Cancer Risk
CPT code 1020T denotes a non-invasive diagnostic test using Raman spectroscopy to evaluate one or more skin lesions and produce a computer-generated probability score for cancer risk. As an emerging optical diagnostic modality, this code captures a technology-driven approach to skin lesion assessment that may affect early detection pathways, referral patterns to dermatology or surgical specialties, and utilization of biopsy procedures.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Coverage policies and claim adjudication for emerging diagnostic technologies vary across these payers, making understanding of coding, clinical indications, and documentation essential for national stakeholders.
Readers will find a concise briefing on the clinical function of the test, the typical outpatient settings where it is performed, and the national relevance of adopting algorithm-driven optical diagnostics. The publication provides benchmark perspectives, summaries of payer coverage stances where available, and applicable policy considerations that influence coding and claims workflows for this diagnostic service. Data not available in the input will be noted where relevant.
Billing Code Overview
CPT code 1020T describes a diagnostic procedure that uses Raman spectroscopy to examine one or more skin lesions. A handheld or table-mounted device shines a laser on each lesion, collects the scattered light, and analyzes the spectral pattern with a computer algorithm to generate a probability score for cancer risk.
Service type: Non-invasive diagnostic imaging/optical spectroscopy of skin lesions
Typical site of service: Outpatient dermatology clinic, ambulatory surgical center, or other outpatient imaging setting
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 52-year-old patient presents to a dermatology clinic with several clinically atypical pigmented skin lesions identified on full skin exam. The patient has a personal history of prior non-melanoma skin cancer and reports recent change in color and border of one lesion. The dermatologist documents digital photography and dermoscopy; lesions are not overtly diagnostic for malignancy and immediate biopsy would be considered invasive. The clinician offers noninvasive Raman spectroscopy testing (1020T) during the same clinic visit. The device is positioned over each suspicious lesion, a low-power laser is applied briefly, scattered light is captured, and the on-board algorithm returns a probability score indicating cancer risk. Results are reviewed with the patient to inform next steps: continued surveillance, targeted biopsy, or referral to surgical dermatology. Typical site of service is an outpatient dermatology clinic or ambulatory surgical center where the Raman spectroscopy device is available. The clinical workflow commonly includes lesion identification, consent for noninvasive optical analysis, acquisition of one or more spectroscopy readings under 1020T, documentation of score and interpretation in the medical record, and coding for any subsequent procedures (biopsy, excision) if performed later in the same encounter or in follow-up.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the day of a procedure | Use when a separately identifiable E/M visit is provided on the same day as 1020T and documented accordingly. |
59 | Distinct procedural service | Use when 1020T is reported with another procedure on the same day that represents a distinct service to different lesions or anatomical sites. |
76 | Repeat procedure or service by same physician | Use if 1020T is repeated later the same day for a lesion if clinically necessary and documented. |
77 | Repeat procedure by another physician | Use if another physician repeats 1020T on the same day. |
52 | Reduced services | Use when 1020T is partially performed or limited and documentation supports reduced service. |
24 | Unrelated E/M service by the same physician during a postoperative period | Use if 1020T is performed during a global postoperative period and an unrelated E/M service is provided. |
54 | Surgical care only | Use when the surgeon bills only the surgical component and another provider bills 1020T as a diagnostic test. |
55 | Postoperative management only | Use if another practitioner performs postoperative management while 1020T is billed by the diagnosing clinician. |
26 | Professional component | Use when billing only the professional component of a split service if applicable by payer policy. |
TC | Technical component | Use when billing only the technical component of the test if payer allows split billing of 1020T. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
207YS0127X | Dermatology | Dermatologists commonly perform lesion evaluation and order or perform optical diagnostics like Raman spectroscopy. |
207Q00000X | General Practice | Primary care providers may refer patients or perform point-of-care noninvasive lesion assessment when trained. |
2084P0800X | Mohs Micrographic Surgery | Surgical dermatologists who perform biopsies/excisions may use spectroscopy results to triage lesions for Mohs procedures. |
207K00000X | Family Medicine | Family physicians in outpatient settings may use noninvasive tools to triage lesions and refer as needed. |
207L00000X | Internal Medicine | Internists who conduct skin exams may use spectroscopy testing for risk stratification prior to dermatology referral. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
D22.9 | Melanocytic nevi, unspecified | Common pigmented lesion evaluated with noninvasive spectroscopy to assess malignancy risk. |
L82.0 | Seborrheic keratosis | Benign-appearing lesion often distinguished from malignant lesions using adjunctive tools like Raman spectroscopy. |
C43.9 | Malignant melanoma of skin, unspecified | High-risk diagnosis that spectroscopy aims to detect or raise suspicion for prompting biopsy. |
C44.91 | Squamous cell carcinoma of skin, unspecified site | Non-melanoma skin cancer that may be suspected after spectroscopy returns a high-risk score. |
L57.0 | Actinic keratosis | Premalignant lesion evaluated in skin exams; spectroscopy can help triage lesions for destruction or biopsy. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
11102 | Tangential biopsy of skin (shave); single lesion | Performed when 1020T indicates high cancer probability and a diagnostic tissue sample is required. |
11100 | Tangential biopsy of skin (shave); single lesion | Alternative shave biopsy code used for removal and diagnosis of suspicious lesions identified or prioritized by 1020T. |
11101 | Tangential biopsy of skin (shave); each additional lesion | Used when multiple lesions identified by 1020T require additional shave biopsies during the same visit. |
11602 | Excision, malignant lesion including margins, trunk, arms, legs; excised diameter 0.6 to 1.0 cm | Used when 1020T results lead to definitive excision for confirmed or highly suspicious malignant lesions. |
17000 | Destruction (e.g., laser surgery, electrosurgery, cryosurgery) of premalignant lesions (e.g., actinic keratoses); single lesion | May be performed for benign or premalignant lesions determined by clinical assessment following 1020T findings. |
93000 | Data not available in the input. | Data not available in the input. |